Announces interim report three will be brought forward
The board of directors of AroCell AB (publ) has taken a decision to bring forward interim report three to November 10, 2015 (previously November 17, 2015) as a consideration to the planned preferential rights issue.For further information: Jan Stålemark, CEOAroCell AB (pub)Tel: +46-706696206info@arocell.comwww.arocell.com About AroCell AB (publ)AroCell AB is a Swedish company that develops standardized modern blood tests to support the prognosis and follow up of cancer patients. AroCell’s new technology is based on patented methods to measure TK1 protein levels, which